143 results
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, Kiora's
8-K
EX-99.1
oetelq gsm9qx73jco
12 Feb 24
Regulation FD Disclosure
5:23pm
8-K
EX-10.2
ac4ap5fhe3nz3kxa
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
u7heww
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-99.1
ca4lo
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
t3sy2qbj 6v
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
khesk
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.2
00o5wageq
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
5fgibx
9 Nov 23
Regulation FD Disclosure
7:02am
8-K
EX-99.1
ofjwv36mmv5egjiz c90
9 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
vk79q4bd
6 Nov 23
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6:05am
8-K
EX-99.1
u4pn hbil8kwo
21 Sep 23
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
7:00am
DEFA14A
EX-99.1
bw7oy
1 Sep 23
Additional proxy soliciting materials
7:00am
8-K
EX-99.1
af17lqxas 5bpma
1 Sep 23
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
7:00am